Retrieve available abstracts of 46 articles: HTML format
Single Articles
June 2025
ASSENAT E, Ben Abdelghani M, Gourgou S, Perrier H, et al Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in
Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized
LEANOX Trial.
J Clin Oncol. 2025 Jun 20:JCO2402754. doi: 10.1200/JCO-24-02754. PubMedAbstract available
May 2025
SHAH P, Philip T They Not Like Us: Evaluating the Diverse Strategies in Locally Advanced Rectal
Cancer Treatment.
J Clin Oncol. 2025;43:1620-1624. PubMedAbstract available
BACHET JB, de Gramont A, Raeisi M, Rakez M, et al Characteristics of Patients and Prognostic Factors Across Treatment Lines in
Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en
Cancerologie Digestive Database.
J Clin Oncol. 2025 May 5:JCO2401968. doi: 10.1200/JCO-24-01968. PubMedAbstract available
VEENSTRA CM, Abrahamse P, Hamilton AS, Ward KC, et al Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in
ATM, CHEK2, or PALB2.
J Clin Oncol. 2025;43:1587-1596. PubMedAbstract available
April 2025
ROUSSEAU B, Cercek A Entering the Era of Multidimensional Prognostication for Personalized Risk
Assessment in Stage III Colon Cancer.
J Clin Oncol. 2025 Apr 11:JCO2500205. doi: 10.1200/JCO-25-00205. PubMed
PIETRANTONIO F, Salvatore L, Esaki T, Modest DP, et al Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus
Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal
Cancer.
J Clin Oncol. 2025 Apr 11:JCO2402026. doi: 10.1200/JCO-24-02026. PubMedAbstract available
February 2025
ZHANG J, Chi P, Shi L, Cui L, et al Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or
Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal
Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years.
J Clin Oncol. 2025;43:633-640. PubMedAbstract available
WIDMAR M, McCain M, Mishra Meza A, Ternent C, et al Cost-Effectiveness of Total Neoadjuvant Therapy With Selective Nonoperative
Management for Locally Advanced Rectal Cancer: Analysis of Data From the Organ
Preservation for Rectal Adenocarcinoma Trial.
J Clin Oncol. 2025;43:672-681. PubMedAbstract available
MORRIS VK, Kennedy EB, Amin MA, Aranha O, et al Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.
J Clin Oncol. 2025;43:605-615. PubMedAbstract available
TAIEB J, Souglakos J, Boukovinas I, Falcoz A, et al Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage
III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR
IDEA-France/HORG-IDEA-Greece Trials.
J Clin Oncol. 2025 Feb 4:JCO2400648. doi: 10.1200/JCO.24.00648. PubMedAbstract available
STINTZING S, Klein-Scory S, Fischer von Weikersthal L, Fuchs M, et al Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic
Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
J Clin Oncol. 2025 Feb 4:JCO2401174. doi: 10.1200/JCO.24.01174. PubMedAbstract available
January 2025
GALLOIS C, Sroussi M, Andre T, Mouillet-Richard S, et al Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment
and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials.
J Clin Oncol. 2025 Jan 31:JCO2302262. doi: 10.1200/JCO.23.02262. PubMedAbstract available
OULADAN S, Orouji E Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in
Solid Tumor Immunotherapy.
J Clin Oncol. 2025 Jan 13:JCO2402081. doi: 10.1200/JCO-24-02081. PubMedAbstract available
RAGHAV KPS, Guthrie KA, Tan B Jr, Denlinger CS, et al Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With
RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A
Randomized Phase II Trial.
J Clin Oncol. 2025 Jan 6:JCO2401710. doi: 10.1200/JCO-24-01710. PubMedAbstract available
November 2024
AVALLONE A, Giuliani F, De Stefano A, Santabarbara G, et al Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and
Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic
Colorectal Cancer: The IMPROVE Trial.
J Clin Oncol. 2024 Nov 22:JCO2400979. doi: 10.1200/JCO.24.00979. PubMedAbstract available
Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in
Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm,
Phase II Trial.
J Clin Oncol. 2024 Nov 19:JCO2402458. doi: 10.1200/JCO-24-02458. PubMed
October 2024
AHN DH, Ridinger M, Cannon TL, Mendelsohn L, et al Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line
Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II
Trial.
J Clin Oncol. 2024 Oct 30:JCO2401266. doi: 10.1200/JCO-24-01266. PubMedAbstract available
SCOTT AJ, Kennedy EB, Berlin J, Brown G, et al Management of Locally Advanced Rectal Cancer: ASCO Guideline.
J Clin Oncol. 2024;42:3355-3375. PubMedAbstract available
XIA F, Wang Y, Wang H, Shen L, et al Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for
Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal
Cancer (TORCH).
J Clin Oncol. 2024;42:3308-3318. PubMedAbstract available
September 2024
CHIBAUDEL B, Raeisi M, Cohen R, Yothers G, et al Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant
Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled
Analysis.
J Clin Oncol. 2024 Sep 4:JCO2400394. doi: 10.1200/JCO.24.00394. PubMedAbstract available
August 2024
LU J, Xing J, Zang L, Zhang C, et al Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer:
The Randomized Phase III RELARC Trial.
J Clin Oncol. 2024 Aug 27:JCO2400393. doi: 10.1200/JCO.24.00393. PubMedAbstract available
TAKASHIMA A, Hamaguchi T, Mizusawa J, Nagashima F, et al Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for
Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter,
Randomized, Open-Label Phase III Trial (JCOG1018).
J Clin Oncol. 2024 Aug 26:JCO2302722. doi: 10.1200/JCO.23.02722. PubMedAbstract available
July 2024
WILLIAMS CJM, Gray R, Hills RK, Shires M, et al Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and
Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer
Within the QUASAR Trial.
J Clin Oncol. 2024 Jul 31:JCO2302030. doi: 10.1200/JCO.23.02030. PubMedAbstract available
SARTORE-BIANCHI A, Marsoni S, Amatu A, Torri V, et al How to Test HER2 for Predicting Resistance to Anti-Epidermal Growth Factor
Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary
Analysis of Biomarkers of CALGB/SWOG 80405.
J Clin Oncol. 2024 Jul 30:JCO2400805. doi: 10.1200/JCO.24.00805. PubMed
PENG C, Kircher SM Neoadjuvant Chemotherapy in Colon Cancer: More Than Just an Optical Illusion.
J Clin Oncol. 2024 Jul 25:JCO2400220. doi: 10.1200/JCO.24.00220. PubMedAbstract available
QIU YY, Yang S, Sun MQ, Huang JH, et al Age May Be an Important Factor Affecting Neoadjuvant Chemotherapy in Patients
With Locally Advanced Colon Cancer.
J Clin Oncol. 2024 Jul 24:JCO2400883. doi: 10.1200/JCO.24.00883. PubMed
KAPADIA P, Zimolzak AJ, Upadhyay DK, Korukonda S, et al Development and Implementation of a Digital Quality Measure of Emergency Cancer
Diagnosis.
J Clin Oncol. 2024;42:2506-2515. PubMedAbstract available
CHLEBOWSKI RT, Aragaki AK, Pan K, Luo J, et al Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the
Women's Health Initiative Randomized Clinical Trial.
J Clin Oncol. 2024 Jul 19:JCO2302092. doi: 10.1200/JCO.23.02092. PubMedAbstract available
JAIN A, Lau NS Liver Transplantation in Colorectal Cancer With Unresectable Liver Metastases:
Disease Biology Cannot Be Ignored.
J Clin Oncol. 2024 Jul 8:JCO2400619. doi: 10.1200/JCO.24.00619. PubMed
June 2024
NOWAK JA, Twombly T, Ma C, Shi Q, et al Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated
Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
J Clin Oncol. 2024 Jun 18:JCO2301680. doi: 10.1200/JCO.23.01680. PubMedAbstract available
ANTONIOTTI C, Rossini D, Pietrantonio F, Salvatore L, et al Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab
With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer:
Updated and Overall Survival Results of the ATEZOTRIBE Study.
J Clin Oncol. 2024 Jun 12:JCO2302728. doi: 10.1200/JCO.23.02728. PubMedAbstract available
KAWAZOE A, Xu RH, Garcia-Alfonso P, Passhak M, et al Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated
Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase
III LEAP-017 Study.
J Clin Oncol. 2024 Jun 4:JCO2302736. doi: 10.1200/JCO.23.02736. PubMedAbstract available
BUTT J, Epplein M Potent Tool: Helicobacter pylori Treatment to Reduce the Risk of Both Gastric and
Colorectal Cancers.
J Clin Oncol. 2024;42:1865-1867. PubMed
May 2024
Erratum: Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With
Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized
Multicenter Trial.
J Clin Oncol. 2024 May 22:JCO2400997. doi: 10.1200/JCO.24.00997. PubMed
April 2024
Erratum: Predicting Functional Recovery and Quality of Life in Older Patients
Undergoing Colorectal Cancer Surgery: Real-World Data From the International
GOSAFE Study.
J Clin Oncol. 2024 Apr 30:JCO2400763. doi: 10.1200/JCO.24.00763. PubMed
HU H, Zhang J, Li Y, Wang X, et al Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront
Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL
Trial.
J Clin Oncol. 2024 Apr 2:JCO2301889. doi: 10.1200/JCO.23.01889. PubMedAbstract available
CHAVEZ-VILLA M, Ruffolo LI, Line PD, Dueland S, et al Emerging Role of Liver Transplantation for Unresectable Colorectal Liver
Metastases.
J Clin Oncol. 2024;42:1098-1101. PubMed
March 2024
GALLOIS C, Shi Q, Pederson LD, Andre T, et al Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon
Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
J Clin Oncol. 2024 Mar 28:JCO2301326. doi: 10.1200/JCO.23.01326. PubMedAbstract available
GAO Z, Zhu Z, Li K Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait
Strategy.
J Clin Oncol. 2024;42:1088. PubMed
MEHTSUN WT, Gupta S Racial Disparities in Receipt of Guideline-Concordant Care for Early-Onset
Colorectal Cancer-We Must Do Better.
J Clin Oncol. 2024 Mar 15:JCO2302186. doi: 10.1200/JCO.23.02186. PubMed
DOMINGO E, Kelly C, Hay J, Sansom O, et al Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer:
Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
J Clin Oncol. 2024 Mar 14:JCO2301648. doi: 10.1200/JCO.23.01648. PubMedAbstract available
LORIA A, Ramsdale EE, Aquina CT, Cupertino P, et al From Clinical Trials to Practice: Anticipating and Overcoming Challenges in
Implementing Watch-and-Wait for Rectal Cancer.
J Clin Oncol. 2024;42:876-880. PubMed
FOKAS E, Smith JJ, Garcia-Aguilar J, Glynne-Jones R, et al Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy
Revisited.
J Clin Oncol. 2024;42:872-875. PubMedAbstract available
BATTAGLIN F, Ou FS, Qu X, Hochster HS, et al HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With
Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.
J Clin Oncol. 2024 Mar 8:JCO2301507. doi: 10.1200/JCO.23.01507. PubMedAbstract available
SHAH SC, Camargo MC, Lamm M, Bustamante R, et al Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a
Large, Nationwide Cohort.
J Clin Oncol. 2024 Mar 1:JCO2300703. doi: 10.1200/JCO.23.00703. PubMedAbstract available
February 2024
RAHBARI NN, Biondo S, Frago R, Feisst M, et al Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and
Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials.
J Clin Oncol. 2024 Feb 27:JCO2301540. doi: 10.1200/JCO.23.01540. PubMedAbstract available